Literature DB >> 8617119

Effects of cisapride on salivary production in normal subjects.

R Patel1, J Launspach, E Soffer.   

Abstract

Cisapride improves reflux esophagitis and enhances esophageal acid clearance. To test the effect of cisapride an salivary production, we enrolled 14 healthy volunteers in a double-blind, randomized, placebo-controlled study. Subjects received cisapride, 10mg per os four times a day, or placebo for three days. Saliva, collected during fasted and fed states, was analyzed for volume and buffer capacity. Buffer capacity was expressed as the volume of 0.01 N HCl needed to titrate 1 ml of saliva to pH 6.1. Both volume and buffer capacity significantly increased during the fed state as compared to the fasted on both cisapride and placebo. Cisapride significantly enhanced the postprandial salivary volume and buffer capacity compared to placebo: 29.6 +/- 11.3 ml vs 22.9 +/- 9.5 ml and 1.07 +/- 0.31 vs 0.89 +/- 0.28, respectively (P< 0.0001). Cisapride's enhancement of salivary flow rate and buffer capacity in the fed state may be another mechanism by which it exerts its beneficial effect in patients with reflux esophagitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617119     DOI: 10.1007/bf02282322

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  Effect of esophageal emptying and saliva on clearance of acid from the esophagus.

Authors:  J F Helm; W J Dodds; L R Pelc; D W Palmer; W J Hogan; B C Teeter
Journal:  N Engl J Med       Date:  1984-02-02       Impact factor: 91.245

2.  Relationship between swallow rate and salivary flow.

Authors:  Y V Kapila; W J Dodds; J F Helm; W J Hogan
Journal:  Dig Dis Sci       Date:  1984-06       Impact factor: 3.199

3.  Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease.

Authors:  S Cucchiara; A Staiano; A Boccieri; M De Stefano; C Capozzi; G Manzi; F Camerlingo; F M Paone
Journal:  Gut       Date:  1990-01       Impact factor: 23.059

4.  Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study.

Authors:  J E Richter; J F Long
Journal:  Am J Gastroenterol       Date:  1995-03       Impact factor: 10.864

5.  Cisapride: influence on oesophageal and gastric emptying and gastro-oesophageal reflux in patients with reflux oesophagitis.

Authors:  B J Collins; R A Spence; R Ferguson; J Laird; A H Love
Journal:  Hepatogastroenterology       Date:  1987-06

6.  Esophageal pH assessment of gastroesophageal reflux in 18 patients and the effect of two prokinetic agents: cisapride and metoclopramide.

Authors:  H Rode; R J Stunden; A J Millar; S Cywes
Journal:  J Pediatr Surg       Date:  1987-10       Impact factor: 2.545

7.  Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis.

Authors:  J P Galmiche; B Fraitag; B Filoche; M Evreux; J Vitaux; P Zeitoun; J Fournet; J C Soule
Journal:  Dig Dis Sci       Date:  1990-05       Impact factor: 3.199

8.  The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat.

Authors:  J Sarosiek; T Feng; R W McCallum
Journal:  Am J Med Sci       Date:  1991-12       Impact factor: 2.378

9.  Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients.

Authors:  P Ceccatelli; J Janssens; G Vantrappen; S Cucchiara
Journal:  Gut       Date:  1988-05       Impact factor: 23.059

10.  Effect of cisapride on postprandial gastro-oesophageal reflux.

Authors:  R H Holloway; J Downton; B Mitchell; J Dent
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

View more
  2 in total

1.  Relevance of ineffective oesophageal motility during oesophageal acid clearance.

Authors:  M Simrén; J Silny; R Holloway; J Tack; J Janssens; D Sifrim
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

Review 2.  Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.

Authors:  Marcello Tonini; Roberto De Giorgio; Fabrizio De Ponti
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.